leisure time -WSS

leisure time

author：explore 2025-10-01 14:59:36 - browse：4415

Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.

For more on what we cover, here’s the story on addiction medicine; here’s the latest on biotech financing; here’s more on Novo Nordisk’s oral obesity treatment; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Head of FDA's diagnostics center, who led through Covid, retires

WSS

Community Health Systems hospitals under DOJ investigation

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Antivenom research: Lessons from HIV applied in search for universal antidote

Inaction leaves children at risk from dangerous chemotherapy drug

TikTok, Instagram influencers need more rules for drug ads

A solution to the after

entertainment

leisure time

focus

The high cost of giving birth even with insurance

What causes osteoarthritis? Researchers study link to brain protein

Trump demands the U.S. pay no more for drugs than other countries … again

Dana Farber says 6 studies to be retracted and 31 corrected

Drug repurposing or repositioning? The language matters

Dario to buy mental health app maker Twill in cash and stock deal

United colonoscopy coverage change 'may cost lives,' doctors say

PBM reform efforts get punted in Congress

Heart attack and stroke risk calculators need revising

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

focus

The inclusion problem at the heart of rehabilitation research

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

There's an unseen cost to disruptive road

Mass General, Mayo Clinic look to monetize custom

Future doctors need a strong humanities education

Obesity drugs seen as possible treatment for liver disease MASH

Wikipedia

hotspot

leisure time

Wikipedia